跳至主要内容
临床试验/CTRI/2021/03/031756
CTRI/2021/03/031756已完成未知

AN OPEN LABEL, SINGLE CENTRE STUDY TO EVALUATE THE PERFOMANCE OF THERAPID ANTIGEN TEST KIT USING NASO-PHARYNGEAL / OROPHARYNGEAL SWAB INCOVID-19 (SARS-CoV2)

Cipla Ltd0 个研究点目标入组 121 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
Cipla Ltd
入组人数
121

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. A voluntarily given data sharing consent from subjects and/or from legally acceptable representative (in case subject is not
  • conscious and oriented).
  • 2. Subjects of 18 years and above with suspected COVID 19 symptoms.
  • 3. No previous or experimental treatment for pneumonia associated with a novel coronavirus infection.

排除标准

  • 1. Subjects with history of diseases that need to be distinguished from new coronavirus infection pneumonia, such as tuberculosis, bacterial or viral pneumonia other than new coronavirus pneumonia, hospital-acquired pneumonia, and other pathogenic pneumonia.
  • 2. Subjects with blood in their sputum or saliva.
  • 3. The investigator determines that the subject is not appropriate to participate in the clinical study.

研究者

发起方
Cipla Ltd

相似试验